$IBRX Income Statement | Understand Stock

$IBRX

$8.63 +$0.82 (10.5%) Close

$IBRX Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Operations

In millions of USD; shares in millions, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Revenue
Product revenue, net
Other revenues
Total revenue
Operating costs and expenses
Cost of sales
Research and development
Nonrelated Party
Related Party
Total research and development
Selling, general and administrative
Nonrelated Party
Related Party
Total selling, general and administrative
Impairment of intangible assets
Total operating costs and expenses
Loss from operations
Other income (expense), net:
Interest and investment income, net
Interest expense (including amounts with related parties)
Interest expense
Nonrelated Party
Related Party
Interest expense related to revenue interest liability
Change in fair value of warrant liabilities
Change in fair value of related-party convertible note
Related Party
Total change in fair value of related-party convertible note
Change in fair value of derivative liabilities
Loss on equity method investment
Other expense, net
Total other expense, net
Loss before income taxes and noncontrolling interests
Income tax benefit
Net loss
Net loss attributable to noncontrolling interests, net of tax
Net loss attributable to ImmunityBio common stockholders
Net loss per ImmunityBio common share - basic (in dollars per share)
Net loss per ImmunityBio common share - diluted (in dollars per share)
Weighted-average number of common shares used in computing net loss per share – basic (in shares)
Weighted-average number of common shares used in computing net loss per share – diluted (in shares)

Comments